InVitro International (IVRO)
USD 0.1
(9.67%)
USD 0.1
(9.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 635.98 Thousand USD | -6.5% |
| 2022 | 680.19 Thousand USD | -15.42% |
| 2021 | 804.2 Thousand USD | -10.4% |
| 2020 | 897.53 Thousand USD | 3.92% |
| 2019 | 863.65 Thousand USD | 25.34% |
| 2018 | 689.05 Thousand USD | -1.23% |
| 2017 | 697.65 Thousand USD | 0.2% |
| 2016 | 696.24 Thousand USD | -13.46% |
| 2015 | 804.53 Thousand USD | 45.26% |
| 2014 | 553.86 Thousand USD | 0.0% |
| 1996 | 600 Thousand USD | 20.0% |
| 1995 | 500 Thousand USD | -44.44% |
| 1994 | 900 Thousand USD | -18.18% |
| 1993 | 1.1 Million USD | 37.5% |
| 1992 | 800 Thousand USD | 300.0% |
| 1991 | 200 Thousand USD | -77.78% |
| 1990 | 900 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 163.91 Thousand USD | 10.57% |
| 2024 Q2 | 171.91 Thousand USD | 4.88% |
| 2024 Q3 | 137.08 Thousand USD | -20.26% |
| 2023 Q2 | 159.31 Thousand USD | -5.89% |
| 2023 Q4 | 148.24 Thousand USD | -6.85% |
| 2023 Q1 | 169.27 Thousand USD | 27.84% |
| 2023 Q3 | 159.15 Thousand USD | -0.1% |
| 2023 FY | 635.98 Thousand USD | -6.5% |
| 2022 Q3 | 195.01 Thousand USD | -6.44% |
| 2022 FY | 680.19 Thousand USD | -15.42% |
| 2022 Q1 | 144.32 Thousand USD | -38.04% |
| 2022 Q2 | 208.44 Thousand USD | 44.43% |
| 2022 Q4 | 132.4 Thousand USD | -32.11% |
| 2021 Q2 | 160.87 Thousand USD | 0.0% |
| 2021 FY | 804.2 Thousand USD | -10.4% |
| 2021 Q4 | 232.94 Thousand USD | -6.07% |
| 2021 Q3 | 247.99 Thousand USD | 54.15% |
| 2020 FY | 897.53 Thousand USD | 3.92% |
| 2019 FY | 863.65 Thousand USD | 25.34% |
| 2018 FY | 689.05 Thousand USD | -1.23% |
| 2017 FY | 697.65 Thousand USD | 0.2% |
| 2016 FY | 696.24 Thousand USD | -13.46% |
| 2015 FY | 804.53 Thousand USD | 45.26% |
| 2014 FY | 553.86 Thousand USD | 0.0% |
| 1997 Q2 | 59 Thousand USD | -80.33% |
| 1997 Q3 | 79 Thousand USD | 33.9% |
| 1997 Q1 | 300 Thousand USD | 50.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q4 | 200 Thousand USD | 100.0% |
| 1996 Q1 | - USD | -100.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 FY | 600 Thousand USD | 20.0% |
| 1995 Q2 | 200 Thousand USD | -33.33% |
| 1995 FY | 500 Thousand USD | -44.44% |
| 1995 Q4 | 300 Thousand USD | 0.0% |
| 1995 Q3 | 300 Thousand USD | 50.0% |
| 1995 Q1 | 300 Thousand USD | 0.0% |
| 1994 Q4 | 300 Thousand USD | 50.0% |
| 1994 Q1 | 400 Thousand USD | 300.0% |
| 1994 Q2 | 100 Thousand USD | -75.0% |
| 1994 Q3 | 200 Thousand USD | 100.0% |
| 1994 FY | 900 Thousand USD | -18.18% |
| 1993 Q1 | 200 Thousand USD | 0.0% |
| 1993 Q3 | 500 Thousand USD | 150.0% |
| 1993 Q4 | 100 Thousand USD | -80.0% |
| 1993 FY | 1.1 Million USD | 37.5% |
| 1993 Q2 | 200 Thousand USD | 0.0% |
| 1992 Q2 | 100 Thousand USD | -50.0% |
| 1992 FY | 800 Thousand USD | 300.0% |
| 1992 Q4 | 200 Thousand USD | 0.0% |
| 1992 Q3 | 200 Thousand USD | 100.0% |
| 1992 Q1 | 200 Thousand USD | 0.0% |
| 1991 Q3 | 200 Thousand USD | -50.0% |
| 1991 FY | 200 Thousand USD | -77.78% |
| 1991 Q4 | 200 Thousand USD | 0.0% |
| 1991 Q2 | 400 Thousand USD | 33.33% |
| 1991 Q1 | 300 Thousand USD | 0.0% |
| 1990 Q2 | 200 Thousand USD | 100.0% |
| 1990 FY | 900 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q3 | 300 Thousand USD | 50.0% |
| 1990 Q4 | 300 Thousand USD | 0.0% |
| 1989 Q3 | 100 Thousand USD | 0.0% |
| 1989 Q4 | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | 429.526% |
| Arrayit Corporation | 2.57 Million USD | 75.302% |
| Atlantic International Corp. | -154.23 Thousand USD | 512.351% |
| Biocept, Inc. | -2.58 Million USD | 124.631% |
| Bioqual, Inc. | 7.42 Million USD | 91.439% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 276 Thousand USD | -130.429% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 99.991% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 64.551% |
| iMD Companies, Inc. | -23.63 Thousand USD | 2790.633% |
| IDenta Corp. | 662.97 Thousand USD | 4.071% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 97.24% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | -719.875% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 90.31% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | 41.796% |
| NovelStem International Corp. | 12 Thousand USD | -5199.875% |
| Optigenex Inc. | -102.96 Thousand USD | 717.665% |
| PharmChem, Inc. | 3.9 Million USD | 83.711% |
| Proteome Sciences plc | 2.09 Million USD | 69.666% |
| Response Genetics, Inc | 3.94 Million USD | 83.866% |
| Rennova Health, Inc. | 6.26 Million USD | 89.854% |
| RushNet, Inc. | 1.1 Million USD | 42.425% |
| ScreenPro Security Inc. | 856.57 Thousand USD | 25.752% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 257.521% |
| Todos Medical Ltd. | 4.31 Million USD | 85.244% |